Use of real-world evidence for oncology clinical decision making in emerging economies

被引:11
|
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [1] USE OF REAL-WORLD EVIDENCE IN CLINICAL DECISION MAKING BY COMMUNITY ONCOLOGISTS
    Kish, J.
    Feinberg, B.
    Hua, D.
    Tchafa, A.
    Smith, Y.
    Klink, A.
    Nabhan, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S48 - S48
  • [2] Payer perceptions of the use of real-world evidence in oncology-based decision making
    Brixner, Diana
    Biskupiak, Joseph
    Oderda, Gary
    Burgoyne, Douglas
    Malone, Daniel C.
    Arondekar, Bhakti
    Niyazov, Alexander
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (08): : 1096 - 1105
  • [3] Real-world evidence enhances decision making
    Malone, Daniel C.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1612 - 1614
  • [4] The Growing Role of Real-World Evidence in Clinical Decision-Making
    Owens, Gary M.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (08): : 401 - 401
  • [5] Making Real-World Evidence More Useful for Decision Making
    Greenfield, Sheldon
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1023 - 1024
  • [6] The evolution of real-world evidence in healthcare decision making
    Williams, David M.
    Evans, Marc
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 443 - 445
  • [7] Real-world Data for Clinical Evidence Generation in Oncology
    Khozin, Sean
    Blumenthal, Gideon M.
    Pazdur, Richard
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)
  • [8] Use of Real-World Evidence in Hematology/Oncology Treatment Optimization
    Vose, Julie M.
    [J]. ONCOLOGY-NEW YORK, 2020, 34 (11): : 459 - 459
  • [9] Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making
    Yuan, Lily
    Rahman, Motiur
    Concato, John
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):
  • [10] The Bar Is High: Evaluating Fit-for-Use Oncology Real-World Data for Regulatory Decision Making
    Lerro, Catherine C.
    Bradley, Marie C.
    Forshee, Richard A.
    Rivera, Donna R.
    [J]. JCO CLINICAL CANCER INFORMATICS, 2024, 8